CD274 and non-small cell lung carcinoma: In metastatic NSCLC, a retrospective study (N = 143) evaluated the differences in baseline characteristics between oligo-acquired resistance (≤3 lesions of disease progression) and systemic acquired resistance in patients treated with first-line PD-(L)1 inhibition.